Serological, genetic and clinical associations with increased health‐care resource utilization in inflammatory bowel disease

Publisher： John Wiley & Sons Inc

E-ISSN： 1751-2980|19|1|15-23

ISSN： 1751-2972

Source： Journal of Digestive Diseases, Vol.19, Iss.1, 2018-01, pp. : 15-23

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

New genetic associations in thiopurine-related bone marrow toxicity among inflammatory bowel disease patients

By Zabala William   Cruz Raquel   Barreiro-de Acosta Manuel   Chaparro María   Panes Julián   Echarri Ana   Esteve Maria   Carpio Daniel   Andreu Montserrat   García-Planella Esther   Domenech Eugeni   Carracedo Angel   Gisbert Javier P   Barros Francisco  

Pharmacogenomics, Vol. 14, Iss. 6, 2013-04 ,pp. : 631-640

Future Medicine

Access to resources Recommend Favorite

Allopurinol–thiopurine combination therapy in inflammatory bowel disease: are there genetic clues to this puzzle?

By Roberts Rebecca L   Gearry Richard B   Barclay Murray L  

Pharmacogenomics, Vol. 11, Iss. 11, 2010-11 ,pp. : 1505-1508

Future Medicine

Access to resources Recommend Favorite

Inflammatory Bowel Disease in the Elderly

By >   Pardi Darrell S.  

Drugs & Aging, Vol. 27, Iss. 8, 2010-08 ,pp. : 617-624

Adis International

Access to resources Recommend Favorite

Macrophages in Inflammatory Bowel Disease

By  

Current Drug Targets. Inflammation & Allergy, Vol. 2, Iss. 2, 2003-06 ,pp. : 155-160

Bentham Science Publishers

Access to resources Recommend Favorite

Pharmacogenetics and Inflammatory Bowel Disease

By  

Current Pharmacogenomics and Personalized Medicine (Formerly Current Pharmacogenomics), Vol. 6, Iss. 3, 2008-09 ,pp. : 201-224

Bentham Science Publishers

Access to resources Recommend Favorite